Andrew Muir
Investment Director @ Midven
Guildford, United Kingdom
Andrew Muir is a seed investor at Midven in Guildford focused on Legal and Advice. Andrew joined Midven in 2004. He is a Director of the Company and Fund Principal of the Rainbow Seed Fund and the Early Advantage fund. After an initial scientific career at Zeneca he went on to roles in research and business development at the medical device company Biocompatibles and then Vice President of Technology for a US start-up indisinfection of medical equipment. He started his career in VC with the £4m per annum Invention and Innovation seed capital fund at NESTA (the National Endowment for Science Technology and the Arts). He has a degree and a PhD in Chemistry from the University of Oxford.Andrew combines a strong scientific and technical grounding with a real commercial pragmatism developed from his operational roles.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 63%
Last updated:
For AI agents: llms.txt
Industries Andrew Muir invests in
Stages Andrew Muir invests in
Countries Andrew Muir invests in
Investment Focus
Industry
- Legal 1 (13%)
- Advice 1 (13%)
- AgTech 1 (13%)
- Farming 1 (13%)
- Medical 1 (13%)
Stage
- Seed 3 (38%)
- Series A 1 (13%)
- Funding Round 1 (13%)
- Venture - Series Unknown 1 (13%)
Country
- United Kingdom 3 (38%)
- United States 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SugaROx
|
SugaROx works on the development of biostimulants aimed at assisting farmers in optimizing productivity on each unit of agricultural land and enhancing the resilience of crop systems in the face of adverse weather conditions, such as drought. | $1.3M / Seed / Aug 19, 2025 | |
Halo X Ray Technologies
|
HALO X-ray Technologies has been spun out of the Imaging Science Group at Nottingham Trent University and the Cranfield Forensic Institute at Cranfield University. We are developing commercially-focused OEM X-ray diffraction solutions based on novel and patented Focal Construct Technology that provides platform capability across a wide range ofapplication areas. Their initial focus lies in the development of HALO solutions for the aviation security and the medical systems markets. We have strong ties to the aviation sector through a long and prestigious research and development programme that has previously realised novel divergent beam X-ray technology (developed and marketed through various incumbent suppliers such as 3DX-ray Ltd) and kinetic depth systems (developed and marketed through Astrophyscis Inc) as 3rd party solutions. We have a clear focus on medical systems and we are currently part of a consortium recentlly awarded an EPSRC grant on Point-of-Care High Accuracy Fracture Risk Prediction. This is an exciting project and we look forward to working with our partners in developing HALO technology for this market. | $2.5M / Series A / Sep 06, 2023 | |
|
SugaROx
|
SugaROx works on the development of biostimulants aimed at assisting farmers in optimizing productivity on each unit of agricultural land and enhancing the resilience of crop systems in the face of adverse weather conditions, such as drought. | $1.7M / Seed / Feb 22, 2023 | |
|
SugaROx
|
SugaROx works on the development of biostimulants aimed at assisting farmers in optimizing productivity on each unit of agricultural land and enhancing the resilience of crop systems in the face of adverse weather conditions, such as drought. | $1.7M / Seed / Feb 22, 2023 | |
Atelerix
|
Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered whenneeded by the addition of a gentle, cell-friendly buffer. This means: Predictability and reliability in drug discovery models and for cells used as therapies Customers can use cells and assays immediately on arrival No need for cryopreservation, nor need for cytotoxic or animal-derived supplements Cells retain their natural state and are not damaged nor altered | $79.6K / Venture - Series Unknown / Sep 03, 2020 | |
|
Atelerix
|
Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered whenneeded by the addition of a gentle, cell-friendly buffer. This means: Predictability and reliability in drug discovery models and for cells used as therapies Customers can use cells and assays immediately on arrival No need for cryopreservation, nor need for cytotoxic or animal-derived supplements Cells retain their natural state and are not damaged nor altered | $917K / May 09, 2019 | |
|
Atelerix
|
Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered whenneeded by the addition of a gentle, cell-friendly buffer. This means: Predictability and reliability in drug discovery models and for cells used as therapies Customers can use cells and assays immediately on arrival No need for cryopreservation, nor need for cytotoxic or animal-derived supplements Cells retain their natural state and are not damaged nor altered | $458K / Seed / Apr 30, 2018 | |
Cagen
|
Cagen is a non-profit entity that assesses and grants accreditation to Graduate School Neurology Programs. | Seed / Mar 06, 2018 |
Co-Investors
About Midven
Midven is a specialist venture capital company providing investment to fast growing small and medium sized enterprises ("SMEs"), run by an energetic, experienced and hands-on team of investment managers.
Midven Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Roger Wood
Director/Shareholder
|
|||
Aanisah Begg
Investment Manager
|
|||
Alexander Leigh
Investment Committee Member
|
|||
|
Andrew Muir
Investment Director
|
|||
Giovanni Finocchio
Investment Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Andrew Muir invest in?
Andrew Muir invests primarily in Legal, Advice and AgTech startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Andrew Muir last invest?
The most recent investment recorded for Andrew Muir closed in Aug 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
